Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
Presentations include investigational late-breaking KERENDIA® (finerenone) data in chronic kidney disease (CKD), including a pooled analysis from studies…